PBMs Lean on Private Label Biosimilars to Cut Costs, Boost Profit
Pharmacy benefit managers (PBMs) are expanding into private label biosimilars to capture cost savings and drive adoption of lower-priced alternatives to biologic drugs. Lumicera Health Services Chief Executive Officer, Ben Heiser, PharmD, shared a comment with Modern Healthcare on what this practice can mean for drug availability and pricing.
MORE ABOUT Ben Heiser
Ben is the Chief Executive Officer, Specialty Pharmacy, at Lumicera Health Services, a full-service national specialty pharmacy accredited by both URAC and ACHC. His accountability includes operations, strategy and business development, and continuing to ensure that Lumicera delivers an exceptional specialty pharmacy program to meet the needs of their patients and partners.
Ben is a Certified Specialty Pharmacist and Lean Six Sigma Greenbelt. He received his Doctor of Pharmacy from the University of Wisconsin and his MBA from the University of Wisconsin — Madison.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
CLARITY FOR ACTION
Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download
Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Related blogs
Navigating Healthcare and Improving Outcomes
PBM 101: Demystifying the Complex World of Specialty Drugs
Unless you work in the pharmacy benefit management (PBM) industry, it’s easy to assume that a “specialty drug” is simply a more expensive prescription. In reality, specialty medications sit in a separate category, with different rules and far bigger consequences…
